Resolution of Advanced Conjunctival Squamous Cell Carcinoma with Cemiplimab Immunotherapy, IFNα-2b, and Retinoic Acid Treatment Over 2 Years of Follow-Up
April 2024
in “
Canadian Journal of Ophthalmology
”
New to retinoic acid? There is a guide in the encyclopedia. Read the guide → 
Studysummary The authors report that a 62-year-old woman with invasive conjunctival squamous cell carcinoma experienced complete remission two years after combining cemiplimab, retinoic acid, and IFNα-2b treatments, highlighting potential utility despite limited availability of IFNα-2b.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
A 62-year-old female with advanced conjunctival squamous cell carcinoma achieved complete remission over 2 years using cemiplimab immunotherapy, topical IFNα-2b, and retinoic acid, despite declining surgery. The treatment was effective with minimal side effects, though it caused persistent eyelash and eyebrow hair loss. This case underscores the potential of these therapies in managing advanced conjunctival SCC and suggests further research into immunotherapy's role in such conditions.
